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Abstract: Brain-derived neurotrophic factor (BDNF) is a member of the neurotrophin growth factor
family, well known for its role in the homeostasis of the cardiovascular system. Recently, the human
BDNF Val66Met single nucleotide polymorphism has been associated with the increased propensity
for arterial thrombosis related to acute myocardial infarction (AMI). Using cardiac magnetic resonance
imaging and immunohistochemistry analyses, we showed that homozygous mice carrying the
human BDNF Val66Met polymorphism (BDNFMet/Met) undergoing left anterior descending (LAD)
coronary artery ligation display an adverse cardiac remodeling compared to wild-type (BDNFVal/Val).
Interestingly, we observed a persistent presence of pro-inflammatory M1-like macrophages and a
reduced accumulation of reparative-like phenotype macrophages (M2-like) in the infarcted heart
of mutant mice. Further qPCR analyses showed that BDNFMet/Met peritoneal macrophages are
more pro-inflammatory and have a higher migratory ability compared to BDNFVal/Val ones. Finally,
macrophages differentiated from circulating monocytes isolated from BDNFMet/Met patients with
coronary heart disease displayed the same pro-inflammatory characteristics of the murine ones.
In conclusion, the BDNF Val66Met polymorphism predisposes to adverse cardiac remodeling after
myocardial infarction in a mouse model and affects macrophage phenotype in both humans and mice.
These results provide a new cellular mechanism by which this human BDNF genetic variant could
influence cardiovascular disease.
Keywords: BDNF Val66Met polymorphism; myocardial infarction; macrophage phenotype;
cardiovascular disease
1. Introduction
Neurotrophins are a family of proteins well known for their critical role in the development,
maintenance, and plasticity of the neurons [1] as well as of the heart and vasculature tissue
development [2–4]. Among the members of this family of proteins, particular attention has been paid
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to the brain-derived neurotrophic factor (BDNF), a key regulator of homeostasis and pathogenesis of
the cardiovascular system [5,6]. BDNF triggers the activation of endothelial cells, vascular smooth
muscle cells, and monocyte/macrophages [7–10], and promotes cardiac microvasculature development
and dynamics [4,11,12], suggesting its important role in orchestrating the mechanisms of repair after
myocardial infarction (MI) [10].
Low circulating BDNF levels were associated with future coronary events and mortality in angina
pectoris patients [13] and with heart failure biomarkers and adverse left ventricular (LV) cardiac
remodeling [14]. Moreover, in different mouse models, low BDNF levels affect cardiac remodeling [15]
and are associated with reduced ejection fraction and vascularization of the border zone of the
infarcted region [16]. Okada et al. [16] provided evidence that these effects are independent of the
cardiomyocyte-specific ablation of BDNF but mainly related to circulating BDNF and its cerebral
output. BDNF, in addition to its ability to favor angiogenesis, promotes the shift of macrophage
phenotype from M1 to M2 with consequent modification of inflammatory microenvironment [9] and,
potentially, with an improvement of cardiac function after MI.
In humans, the presence of a single nucleotide polymorphism (SNP) in the BDNF gene, leading
to valine to methionine substitution at position 66 in the prodomain region of the BDNF protein
(BDNF Val66Met) determines the reduction of cerebral BDNF levels [17], and it is related to mood
disorders and neurodegenerative diseases [18]. Several studies investigated the potential implications
of this mutation in the context of cardiovascular diseases, but their results were controversial [19–21].
We showed that Met homozygosity is associated with arterial thrombosis in a knock-in mouse model
and with increased risk of acute myocardial infarction (AMI) in humans [21]. Therefore, the objective of
this study was to determine, in a mouse model carrying the BDNF Val66Met polymorphism, the impact
of the mutation on cardiac remodeling after MI focusing on the characterization of macrophage
phenotype. Besides, to support the potential relevance of the data obtained in the animal model we
analyzed the macrophages spontaneously differentiated from monocytes isolated from homozygous
Val or Met human carriers.
2. Materials and Methods
2.1. Animal Studies
BDNF Val66Met mice [22] were generated by heterozygous BDNF Val/Met interbreeding and
offspring were genotyped by PCR analysis of tail tip-derived genomic DNA. Animal studies were
in conformity with the European ethics legislation and approved by the Italian National Ministry of
Health (375-2017PR and 270-2019PR). All procedures were performed in 10–12-week-old wild-type
control (BDNFVal/Val) or BDNFMet/Met mice. Surgical procedures were performed in mice anesthetized
with ketamine chlorhydrate (75 mg/kg; Intervet, Segrate, Milan, Italy) and medetomidine hydrochloride
(1 mg/kg; Virbac, Milan, Italy).
2.2. Left Anterior Descending (LAD) Coronary Artery Ligation Model
As previously described [23], MI was induced in anesthetized mice by ligation of the left anterior
descending (LAD) coronary artery using a 7-0 silk suture through left thoracotomy under anesthetized
mice and mechanical ventilation. Successful ligation was verified by visual inspection of the left
ventricular (LV) apex for myocardial blanching, indicating interruption of the coronary blood flow.
Atipamezole (0.5 mg/kg, Virbac, Milan, Italy) was administered to encourage animal awakening,
and then the animals were extubated and monitored.
Based on our previous data [24], infarcted mice with a left ventricular ejection fraction (LV EF),
within the range 35–45%, obtained by cardiac magnetic resonance imaging (cMRI) at 24 h, were included
into the study and randomized into two different experimental protocols as follows.
Protocol 1. The impact of BDNFVal66Met polymorphism on cardiac remodeling following MI
was evaluated on BDNFVal/Val and BDNFMet/Met mice. Mice were longitudinally examined before
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LAD ligation (baseline) and 24 h, 1, 4, and 8 weeks after surgery by cMRI in order to evaluate LV
parameters. After the last cMRI visualization, mice were euthanized and cardiac tissue collected for
histological analyses.
Protocol 2. The implication of macrophage polarization in cardiac remodeling following MI was
evaluated on BDNFVal/Val and BDNFMet/Met sacrificed at 3, 5, and 7 days after MI.
2.3. Cardiac Magnetic Resonance Imaging
Mice were anesthetized with inhaled 1% isoflurane (Merial, Toulouse, France) in 100% oxygen,
fixed on a holder and placed into the 3.8-cm coil. The temperature was monitored rectally. The images
were acquired using a 4.7T vertical-bore MR magnet (Bruker, Germany) and a retrospective gated cine
gradient echo sequence with the following parameters: Echo time (TE) 1.9 ms, repetition time (TR)
10 ms, field of view 4 × 4 cm2, acquisition matrix 128 × 128 pixels, slice thickness 1.3 mm, 6–8 axial
slices spaced 1 mm to fully cover the LV.
The magnetic resonance images were analyzed using custom software implemented in Python
environment along the lines [24] in order to obtain end-diastolic (LV EDV), end-systolic (LV ESV),
and stroke volumes (LV SV); ejection fraction (LV EF); and ventricular mass (LV mass).
2.4. Tissue Collection and Section Preparation
In order to prepare specimens for histological analysis, the abdominal aorta was cannulated and
the heart was arrested in diastole, with 2 mL of a solution of 0.1 M CdCl2 and 1 M KCl, and retrogradely
perfused with 0.01 M phosphate saline buffer (PBS) and then with 4% (v/v) phosphate-buffered formalin
for 10 min each. Hearts were collected and tissues post-fixed in 4% phosphate-buffered formalin for
24 h and embedded in paraffin. Consecutive 8-µm heart axial (along the apex-basis axis) sections
were prepared.
2.5. Determination of Infarct Size and Cardiomyocytes’ Cross-Sectional Area
MI size was determined on LV axial section (one for each millimeter of LV). To define the infarct
lengths, endocardial infarct length was taken as the length of endocardial infarct scar surface that
included greater than 50% of the whole thickness of myocardium, and epicardial infarct length as
the length of the transmural infarct region. Epicardial infarct ratio was obtained by dividing the
sum of epicardial infarct lengths from all sections by the sum of epicardial circumferences from all
sections. Endocardial infarct ratio was calculated similarly. Infarct size derived from this approach
was calculated as ((epicardial infarct ratio + endocardial infarct ratio)/2) × 100 [25].
For collagen staining, heart sections were incubated in 0.1% Sirius red solution (Direct Red 80,
Sigma-Aldrich, Saint Louis, MO, USA), mounted with DPX (Distyrene and xylene) mountant for
microscopy, and images acquired with a high-resolution digital camera using 1:1 macro-lens. Myocytes’
cross-sectional area (MCSA) was measured on 3 tissue sections from each heart stained with germ
agglutinin–Alexa Fluor 488, incubated with Hoechst 33258 nuclear stain (Invitrogen, Waltham, MA,
USA), and then mounted using fluorescence mounting medium (Dako, Milan, Italy). Images from the
non-infarcted region (222 µm x 166 µm) were acquired using a fluorescence microscope (Axiovert 200,
Zeiss, Jena, Germany). Cross-sectional area of 100–150 cardiomyocytes from each mouse was measured
on transversally sectioned cells with circularity greater than 0.6 and round nuclei. All quantitative
analyses were performed in blind using Photoshop CS6 (Adobe System) or Image J (U.S. National
Institutes of Health, Bethesda, MD, USA).
2.6. Cardiac Macrophage Extraction and Flow Cytometer Analysis
Hearts were collected from mice 3, 5, or 7 days after LAD ligation. Macrophages were isolated from
the heart following a previously published protocol [26]. Briefly, tissue was minced in small pieces (2–3
mm length) and digested with 600 U/mL collagenase II and 10 U/mL DNase I (Sigma-Aldrich, Saint Louis,
MO, USA) in Hanks buffered saline solution (Sigma-Aldrich, Saint Louis, MO, USA) and filtered
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through a 30-µm separation filter to generate a single-cell suspension. Macrophages were isolated
after gradient centrifugation at the interphase between 35% and 70% Percoll solutions (Sigma-Aldrich,
Saint Louis, MO, USA), then washed with PBS, permeabilized, and stained with the following
fluorophore-conjugated antibodies: CD206-APC (eBioscience-Thermo Fisher, Paisley, Scotland, UK),
CD68-PE (eBioscience-Thermo Fisher, Paisley, Scotland, UK), and CD11c-FITC (eBioscience-Thermo
Fisher, Paisley, Scotland, UK). Nonspecific staining was eliminated, incubating the same number of
cells as in the surface markers’ antibody tube with isotype control antibody, matched to the surface
marker antibody’s host species and class. Samples were analyzed by NovoCyte flow cytometer
(ACEA Biosciences, San Diego, CA, USA) and the percentage of positive cells was compared with
fluorescence-labeled isotype controls. A minimum of 10,000 events was collected in the CD68+ gate by
flow cytometry.
2.7. Mouse Peritoneal Macrophage Isolation
Seventy-two hours after thioglycollate broth injection, macrophages were harvested from the
peritoneum with ice-cold PBS, centrifuged, and suspended in DMEM (Dulbecco’s Modified Eagle
Medium) medium (Lonza, Basel, Switzerland) supplemented with penicillin and streptomycin (100 U/mL
each) (Gibco, Rodano, Milan, Italy) and plated as previously described [27]. After one hour, plates were
washed and adherent cells were left for four hours in DMEM medium after which they were lysed
TRIzol Reagent (Sigma-Aldrich, Saint Louis, MO, USA) or within RIPA (Radioimmunoprecipitation
assay) buffer (1% Triton X-100 in 50 mM Tris–HCl (pH 7.5) plus 1 mM phenylmethylsulfonyl fluoride,
1 mM N-ethylmaleimide, 2 µg/mL leupeptin, 1 mM NaF, 1 mM benzamidine, and 1 mM sodium
vanadate, all from Sigma-Aldrich, Saint Louis, MO, USA. After incubation on ice for 1 h, the lysates
were centrifuged at 12,000 × g for 30 min for BDNF detection and frozen for further analyses.
2.8. BDNF Analysis
BDNF was measured by commercial Emax Immunoassay system kit (Promega, Madison, WI,
USA) in whole macrophages’ extract lysed in RIPA buffer.
2.9. Migration Assay
Boyden chamber assay. Cell migration under unstimulated conditions and in response to a
migratory factor was assessed by using a 48-well microchemotaxis Boyden chamber [28]. Briefly,
triplicate wells of the lower part of the microchemotaxis chamber were filled with DMEM (Lonza, Basel,
Switzerland) with 0.2% BSA (Bovine Serum Albumin) ± 20 ng/mL MCP-1 (Monocyte Chemoattractant
Protein-1) (Thermo Fisher, Paisley, Scotland, UK). A 5-µm pore diameter polycarbonate membrane
coated with collagen was placed on the top and the chamber was tightened. Peritoneal macrophages
(1 × 105 cells) were added to the upper wells for 3 h at 37 ◦C. The membrane was then removed,
adherent cells on the top were eliminated, and the membrane was stained with Diff-Quik reagents.
Each test group was assayed in at least 3 replicates and pictures of typical fields were taken under
high-power light microscopy. Migrated cells were evaluated by blind counting cells in 12 random
fields for each experimental group with the Image J software.
The agarose spot migration assay was adapted from Ahmed et al. [29]. Ten µL of low-gelling
temperature agarose (Sigma-Aldrich, Saint Louis, MO, USA) containing vehicle, LPS (Lipopolysaccharide)
(10 ng/mL), or MCP-1 (20 ng/mL) (Thermo Fisher, Paisley, Scotland, UK) were put on the surface
of a microscope glass slide coated with gelatin. Then, 5 × 105 macrophages were seeded on every
microscope glass slide with DMEM medium (Lonza, Basel, Switzerland) supplemented with penicillin
and streptomycin (100 U/mL each), non-adherent cells were washed with PBS after 1 h, and macrophages
were allowed to migrate for 24 h in DMEM medium (Lonza, Basel, Switzerland) supplemented with
penicillin and streptomycin (100 U/mL each) (Gibco, Rodano, Milan, Italy) and 10% of serum (Euroclone,
Pero, Milan, Italy). Photos were taken using a 5 ×magnification with a Zeiss Axioskop (Zeiss, Jena,
Germany) equipped with an intensified charge-coupled device (CCD) camera system (Photometrics,
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Tucson, AZ, USA). The number of migrated macrophages was determined by blind counting cells in 8
random fields for each experimental group.
2.10. Human Studies
Homozygous BDNFVal/Val and BDNFMet/Met carriers (age 50–80 y) were identified within a large
set of male patients with a clinical history of stable angina or acute coronary syndrome followed by
coronary artery bypass graft surgery, previously genotyped by our group for the BDNF Val66Met
polymorphism [21]. Patients were matched for genotype, age clinical presentation of coronary heart
disease as stable and unstable angina or acute myocardial infarction, and pharmacological treatments.
All the patients were under aspirin and statins, one patient per group was under anticoagulant, and 92%
of BDNFVal/Val patients and 71% of BDNFMet/Met patients were under beta-blockers. After selected
candidates provided written informed consent, a detailed anamnesis and physical examination were
carried out and venous blood was obtained at fasting from an antecubital vein. The study complied
with the declaration of Helsinki and was approved by the Institutional Review Board and Ethical
Committee of Centro Cardiologico Monzino IRCCS (Istituto di ricovero e cura a carattere scientifico)
(R455/16-CCM 471). Human mononuclear cells were separated from venous blood by centrifugation
on Ficoll-Paque Plus (Sigma-Aldrich, Saint Louis, MO, USA) density gradient, and monocytes were
isolated by selective adhesion [30]. Monocyte to macrophage differentiation was obtained by cultivating
monocytes in Medium 199 (Lonza, Basel, Switzerland) supplemented with l-glutamine, penicillin, and
streptomycin (all from Gibco, Rodano, Milan, Italy), and 10% of autologous serum at 37 ◦C and 5%
CO2 for seven days, as previously described [31].
2.11. Quantitative Real-Time PCR (qPCR)
Total cellular RNA was isolated from human and murine macrophages using TRIzol Reagent
(Sigma-Aldrich, Saint Louis, MO, USA) and a Direct-zol RNA extraction kit (Zymo Research, Irvine,
CA, USA) according to the manufacturer’s instructions. One µg of RNA was reverse transcribed using
the iScript Advanced cDNA Synthesis Kit (Bio-Rad Laboratories, Segrate, Milan, Italy).
Samples of cDNA were incubated in 15 µL Luna®Universal qPCR mix containing the specific
primers and fluorescent dye SYBR Green (New England Biolabs, Pero, Milan, Italy). RT-qPCR was
carried out in triplicate for each sample on the CFX Connect real-time System (Bio-Rad Laboratories,
Segrate, Milan, Italy), as previously described [32]. Gene expression was analyzed using parameters
available in CFX Manager Software 3.1 (Bio-Rad Laboratories, Segrate, Milan, Italy). Then, qPCR was
carried out using the primer sequences shown in Table S1.
2.12. Statistical Analyses
Statistical analyses were performed using GraphPad Prism 7 software (San Diego, CA, USA).
Data were analyzed by Student’s t-test or by 2-way-ANOVA (with repeated measures when necessary)
for main effects of treatment, time, and genotype, followed by a Bonferroni post hoc analysis. p values
of less than 0.05 were considered statistically significant. Data represent mean ± SEM. All human
performed analyses were adjusted for age and drug treatments.
3. Results
3.1. BDNF Val66Met Polymorphism Affects Left Ventricle Remodelling After LAD Ligation
To establish the effect of BDNF Val66Met polymorphism in heart remodeling after MI, the
BDNFVal/Val and homozygous BDNFMet/Met mice underwent left anterior descending (LAD) coronary
artery ligation, and cardiac morphology and function were assessed by cMRI at 24 h and 1, 4,
and 8 weeks after surgery. At baseline, BDNFVal/Val and BDNFMet/Met mice displayed normal and
comparable heart parameters (Table 1).
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Table 1. Left ventricular (LV) parameters obtained by cardiac magnetic resonance imaging
(cMRI) analysis.
Genotype Time
Cardiac Magnetic Resonance Imaging (cMRI) Parameters
LV EF (%) LV EDV (µL) LV ESV (µL) LV Mass (mg)
BDNFVal/Val
baseline 67.5 ± 1.7 47.2 ± 3.3 15.6 ± 1.7 82.3 ± 3.1
24 h 37.2 ± 1.8 59.9 ± 4.7 37.4 ± 2.8 72.2 ± 3.8
1 week 36.9 ± 1.8 71.7 ± 5.9 45.1 ± 3.9 88.0 ± 6.5
4 weeks 36.1 ± 2.2 92.1 ± 4.5 59.1 ± 4.2 84.8 ± 3.3
8 weeks 31.8 ± 2.9 91.0 ± 6.6 62.7 ± 6.3 89.2 ± 3.8
BDNFMet/Met
baseline 69.9 ± 2.4 43.7 ± 2.3 13.5 ± 1.7 80.8 ± 3.5
24 h 36.2 ± 1.1 73.1 ± 1.8 46.7 ± 1.7 82.8 ± 3.5
1 week 33.5 ± 3.1 97.5 ± 7.2 66.5 ± 7.1 97.6 ± 3.1
4 weeks 26.0 ± 2.4 * 128.0 ± 12.9 * 96.9 ± 11.8 ** 95.6 ± 3.8
8 weeks 25.5 ± 2.5 140.2 ± 13.3 *** 107.1 ± 13.0 *** 104.1 ± 3.8 *
BDNFVal/Val: N = 7 mice, BDNFMet/Met: N = 10 mice; LV: left ventricular; EF: ejection fraction; EDV: end-diastolic
volume; ESV: end-systolic volume. Data are expressed as mean ± SEM. Two-way ANOVA followed by Bonferroni
post-hoc analysis, * p < 0.05, ** p < 0.01, and *** p < 0.001 vs BDNFVal/Val.
As a consequence of MI, 24 h after LAD ligation an important reduction of left ventricular ejection
fraction (LV EF%) was observed in both experimental groups (BDNFVal/Val: −45 ± 2%, BDNFMet/Met:
−47 ± 2%). Although BDNFMet/Met mice showed an increase of left ventricle end-diastolic and systolic
volumes compared to BDNFVal/Val group (LV EDV: BDNFVal/Val: +27 ± 5%; BDNFMet/Met: +70 ± 7%
and LV ESV: BDNFVal/Val: +149 ± 17%; BDNFMet/Met: +294 ± 48%), no significant difference in the
cMRI parameters was detected either at 24 h or 1 week after LAD ligation. Four weeks after surgery,
BDNFMet/Met mice displayed a significant increase in LV EDV and LV ESV compared to BDNFVal/Val
(p < 0.05 for LV EDV and p < 0.01 for LV ESV) with a concurrent LV EF% reduction (p < 0.05). The LV
EDV and the LV ESV differences were maintained until 8 weeks after LAD ligation, when also a
significant increase of LV mass was observed in BDNFMet/Met (p < 0.05) (Table 1). At the same time
point, histological examination showed that BDNFMet/Met mice have a larger infarct size % (p < 0.05)
(Figure 1A,B) and a greater myocyte cross-sectional area (MCSA) in non-infarcted left ventricular
regions (p < 0.05) than BDNFVal/Val mice (Figure 1C,D).
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Figure 1. Characterization of the infarcted hearts isolated from BDNFVal/Val (Val/Val) and BDNFMet/Met
(Met/Met) mice. (A) Representative photomicrographs of infarct size evaluated from the base (left) to
the apex (right) by Sirius red staining measured at 8 weeks after surgery. (B) Infarct size expressed as
percentage of the length of the i farct scar on the LV total circumferential le gth. (C) Representative
immunofluorescence (40×, scale bar: 50 µm) and (D) measurement of myocyte cross-sectio al area
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3.2. BDNF Val66Met Polymorphism Affects the Physiological Accumulation of M1- and M2-Like Macrophages
after LAD Ligation
Ischemia triggers the accumulation of macrophages that plays a fundamental role in post-MI
damage and in the subsequent cardiac remodeling [33]. Indeed, it is well known that the macrophage
phenotype regulates the inflammatory phase and influences the reparative phase favoring collagen
deposition and scar formation. Then, we profiled macrophages’ accumulation in the myocardium and
we investigated the cardiac macrophage subsets at 3, 5, and 7 days after MI.
The infarct induced, in both BDNFVal/Val and BDNFMet/Met mice, the accumulation of macrophages
(CD68+ cells), which peaked on day 5. Of note, at day 5, infarcted BDNFMet/Met heart accumulated
a greater number of macrophages compared to BDNFVal/Val (Figure 2A,B), suggesting a prolonged
recruitment of macrophages in the heart of mutant mice.
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days) after the induction of myocardial infarction in BDNFVal/Val (white bar graph) and BDNFMet/Met
(grey bar graph) mice. (A) Representative FACS plots showing the gating strategy for CD11c+
(CD11c+/CD68+) and CD206+ (CD206+/CD68+). Quantification of macrophage subsets according to
the expression of (B) CD68 positive cells, CD206, and CD11c positive cells at (C) 3, (D) 5, (E) 7 days
after LAD. N = 6/group/time; * p < 0.05 and ** p < 0.01 BDNFVal/Val vs. BDNFMet/Met; ◦◦ p < 0.01 and
◦◦◦◦ p < 0.001 BDNFVal/Val comparison at different time points; §§§§ p < 0.001 BDNFMet/Met comparison
at different time points.
Accordi g to the literature, we found a progressive reduction in classically activated macrophages
(CD11c+/CD68+, pro-inflammatory M1-like) associated with a concomitant increase in alternatively
activated macrophage markers (CD206+/CD68+, M2-like) from day 3 to day 7 after LAD ligation
(Figure 2C–E) in BDNFVal/Val mice.
Remarkably, on day 5, BDNFMet/Met mice still showed a persistent presence of CD11c+/CD68+
macrophages and, of consequence, a reduced accumulation of CD206+/CD68+ macrophages, compared
to BDNFVal/Val (Figure 2C–E).
3.3. BDNF Mutation Influences Murine Macrophage Polarization
To assess whether the BDNF Val66Met affects macrophage polarization, in vitro studies were
performed in resident and thioglycollate-elicited peritoneal macrophages isolated from BDNFVal/Val
and BDNFMet/Met mice.
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Flow cytometry analysis revealed a higher number of CD11c+ and lower abundance of
CD206+ in cells isolated from BDNFMet/Met when compared to BDNFVal/Val in both resident and
thioglycolate-elicited macrophages (Figure 3A–C). In addition, BDNFMet/Met thioglycolate-elicited
peritoneal macrophages expressed significantly higher levels of marker CD80 (BDNFVal/Val: 1.03 ± 0.02
vs. BDNFMet/Met: 1.35 ± 0.16, p < 0.05) and lower levels of alternatively activated macrophage markers
CD206 (BDNFVal/Val: 1.02 ± 0.01 vs. BDNFMet/Met: 0.63 ± 0.16, p < 0.05) and CD163 (BDNFVal/Val:
1.00 ± 0.001 vs. BDNFMet/Met: 0.58 ± 0.08, p < 0.001), with an increase in the CD80/CD206 and
CD80/CD163 ratio (Figure 3A,B). The abnormal ratio in classically/alternatively activated macrophage
markers detected in mutant macrophages was associated with a greater expression of inflammatory
cytokines (Figure 3F–H) that well reflected their predominant pro-inflammatory (M1-like) phenotype.
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Interestingly, BDNF Val66Met polymorphism reduced the levels of BDNF in macrophages
(Figure 3I) without affecting its mRNA levels (Figure 3J), and increased the expression of its specific
receptor TrkB-T2 (Figure 3K). In addition, a significant reduction of both Sort1 and Sorl1, known to
mediate the trafficking and sorting of TrkB receptors of BDNF, were found in mutant macrophages
(Figure 3L,M).
3.4. BDNFVal66Met Polymorphism Affects Murine Macrophages’ Shape and Migratory Ability
As previously described in several studies [34], here we observed that the pro-inflammatory
macrophage phenotype was associated with morphological and functional changes. In particular,
the microscopic examination of macrophages showed that cells isolated from BDNFMet/Met mice
exhibited mainly a round morphotype compared to BDNFVal/Val that, in turn, were prevalently
spindle/elongated (Figure 4A,B).
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Figure 4. Morphology and functionality of BDNFVal/Val (Val/Val) and BDNFMet/Met (Met/Met) peritoneal
macrophages. (A) Representative images of phase-contrast microscopy and (B) Giemsa staining, 40×,
scale bar: 50 µm. (C) Migratory ability analyzed by agarose spot migration assay. N = 4 independent
experiments; * p < 0.05, and ** p < 0.01 Val/Val vs. Met/Met; ◦ p < 0.05 and ◦◦◦ p < 0.005 vs. BDNFVal/Val
control macrophages; §§ p < 0.001 vs. BDNFMet/Met control macrophages.
In addition, in vitro cell migration studies showed that elicited BDNFMet/Met macrophages
displayed a higher migratory ability compared to BDNFVal/Val (Figure 4C and Figure S1). This increase
still remained significantly different both in response to MCP-1 and after LPS stimulation, providing
evidence of a broad migratory alteration induced by the presence of this mutation (Figure 4C and
Figure S1).
3.5. Effect of BDNFVal66Met Polymorphism on Human Macrophages Phenotype
Finally, we compared the phen type of monocyte-derived macrophages isolated from BDNFVal/Val
and BDNFMet/Met coronary artery disease (CAD) patients representing the subset of the same cohort of
CAD patients previously analyzed [21].
As observed in mouse peritoneal macrophages, the macrophage obtained from BDNFMet/Met
subjects showed a higher percentage of round morphotype, while BDNFVal/Val macrophages had a
prevalently elongated/spindle shape (Figure 5A).
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Figure 5. Characterization of BDNFVal/Val (Val/Val, white bar graph) and BDNFMet/Met (Met/Met, grey
bar graph) human macrophages. (A) (i) Bright field representative images (20×, scale bar: 50 µm) and
(ii) frequency in round, spindle, and undefined human macrophages. (B) mRNA levels of genes r lated
to M1/M2 markers ratio, (C–E) inflammatory genes (IL-6, TNF-α, and COX-2) and (F) BDNF. N = 13/14
patient genotype/g p, * p < 0.05, and ** p < 0.01.
In addition, in the presence of the mutation, we observed an increase in the transcript level of CD80
(BDNFVal/Val: 1.00 ± 0.26; BDNFMet/Met: 3.52 ± 0.87, p < 0.05) and lower levels of CD206 (BDNFVal/Val:
1.10 ± 0.20; BDNFMet/Met: 0.28 ± 0.08, p < 0.01) with an increase in the CD80/CD206 ratio (Figure 5B).
Finally, BDNFMet/Met human macrophages expressed a significantly higher level of inflammatory genes
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(Figure 5C–E). As showed above in mouse macrophages, the BDNF mRNA levels were similar between
Met and Val carrier patients (Figure 5F).
4. Discussion
Despite the advances in prevention and treatment, cardiovascular diseases remain the leading
cause of morbidity and mortality in the world, with an estimated 23.3 million deaths by 2030 [35].
Among the pathologies, myocardial infarction represents a major burden since it might result in heart
failure if it does not prove fatal immediately.
In the present study, using the humanized BDNF Val66Met homozygous knock-in mice, we found
that the BDNF Val66Met polymorphism predisposes to adverse cardiac remodeling with a persistent
presence of pro-inflammatory macrophages and a reduced accumulation of reparative macrophage
phenotype in the infarcted heart.
The macrophage population in mouse ischemic heart was heterogeneous and changes during the
time after the event. In particular, pro-inflammatory (M1) macrophages were dominant at day 1–3
post-MI, whereas reparative (M2) macrophages represented the majority between days 5–7 [36]. Indeed,
the pro-inflammatory M1 macrophages played a key role in the first step after damage, releasing several
inflammatory factors, including cytokines, chemokines, growth factors, and Matrix metallopeptidases
(MMPs), in order to clear the damaged area from cell debris and degrade the extracellular matrix [37].
The anti-inflammatory M2 macrophages were involved in the reparative processes, they produced
anti-inflammatory, pro-angiogenic, and pro-reparative factors in order to facilitate neo-angiogenesis
and scar repair [38].
The correct temporal window during which pro-inflammatory or reparative macrophages are
present in the infarcted area is fundamental for the correct process of cardiac remodeling, improving
myocardial repair, and function post-MI [37]. The persistence of pro-inflammatory macrophages
for a prolonged period can lead to the expansion of infarct size and to a delayed resolution of
inflammation [39]. Thus, extensive matrix degradation, compromised ventricular wall integrity, cardiac
rupture, and fibrosis are followed by impaired systolic function, chamber dilation, and ventricular
hypertrophy [40]. Therefore, the adverse cardiac remodeling observed in BDNFMet/Met mice could well
be traced back to the persistent presence of pro-inflammatory, rather than reparative, macrophages after
MI. However, we cannot exclude that other leukocyte populations might affect adverse cardiovascular
remodeling in BDNFMet/Met mice. Here, we showed that mutation improves M1-like polarization.
However, at day 3 post-MI, no difference between the two groups was observed, suggesting that
the presence of a highly inflammatory cardiac environment has the same impact on the polarization
of both BDNFVal/Val and BDNFMet/Met macrophages. In addition, mutation prevents an appropriate
M2-like polarization. Interestingly at day 5 post-MI (when M2 phenotype starts to be favored),
the difference between genotypes occurs, suggesting a likely defect to induce a proper M2 polarization.
Specific studies must be carried out to unravel this important issue.
Interestingly, a similar macrophage shift was recently observed also in the epidydimal adipose
tissue of BDNFMet/Met mutant mice, where macrophages expressed higher levels of pro-inflammatory
marker CD80 compared to BDNFVal/Val mice [32], suggesting that this mutation might predispose
macrophages to a pro-inflammatory phenotype in different tissues and experimental conditions.
In line with the in vivo model, ex vivo studies showed that the Met mutation predisposes to
M1-like phenotype. Indeed, according to the definition of M1 or M2 macrophage phenotype [41],
both human and mouse BDNFMet/Met macrophages displayed a higher ratio between CD80 and CD163
and/or CD206 markers, greater levels of pro-inflammatory cytokines IL-6 and TNF-α, and lower levels
of TGF-β and IL-10, and increased migratory ability than BDNFVal/Val macrophages. In addition,
the abnormal ratio between round and spindle macrophages observed in Met carriers well reflects this
phenotype. Actually, round macrophages are characterized by genes encoding for the pro-inflammatory
cytokines and chemokines (CCR2+), showing an M1-like pro-inflammatory phenotype. On the contrary,
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spindle-shaped macrophages overexpress IL-10 and TGFβ, typical of M2 anti-inflammatory/reparative
(CCR2−) macrophages, and possess wound repair ability [42].
After MI, the damaged cardiac tissue was able to initiate an influx of CCR2+ macrophages
that produce pro-inflammatory cytokines [43,44], displaying an M1-like phenotype. Interestingly,
suppression of the CCR2 receptor activity by specific siRNA and inhibition of CCR2+ macrophage
recruitment in the ischemic area significantly reduced infarct size in mouse models and concomitantly
decreased MCP-1, IL-1-β, IL-6, and TNF-α expression [39,42,45]. In contrast, depletion of resident
cardiac CCR2- macrophages in a murine model of myocardial infarction increased infarct area, reduced
LV systolic function, and exaggerated LV remodeling [42]. Therefore, the migration of circulating
monocytes and resident macrophages to the damaged area plays a key role in the subsequent cardiac
remodeling. In this regard, future studies will be necessary to establish the specific contribution of
circulating monocytes and resident macrophages as well as the role of the cardiac environment in this
animal model.
For the first time, we provided evidence that the BDNF Val66Met polymorphism affects the
macrophage phenotype in both an animal model and in humans. In particular, macrophages spontaneously
differentiated from BDNFMet/Met patients displayed an inflammatory M1-like phenotype, despite that
the patients were under treatment with statins. Indeed, it is well known that these compounds,
beyond their strong lipid-lowering effect, polarize the macrophages’ phenotype toward M2, decreasing
their inflammatory profile [46–48]. Thus, our data suggest that statin treatment may not be sufficient
to counteract the inflammatory macrophage phenotype of BDNFMet/Met patients. Based on these data,
we can speculate that a phenotypic alteration in BDNFMet/Met macrophages might affect the onset and
progression of cardiovascular disease; although, it will be important to confirm all the modifications
observed in mutant mouse macrophages also in human.
5. Conclusions
To our knowledge, these results provide new insights into the already well-established role
of BDNF in the cardiovascular system, suggesting a new cellular mechanism by which the BDNF
Val66Met polymorphism could affect pathological cardiovascular conditions. Further studies are
necessary to transfer this information into daily clinical practice.
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